Ginette-35
| Dosaggio del prodotto: 0.035mg+2mg | |||
|---|---|---|---|
| Confezione (n.) | Per compresse | Prezzo | Acquista |
| 42 | €1.60 | €67.06 (0%) | 🛒 Aggiungi al carrello |
| 63 | €1.50 | €100.58 €94.22 (6%) | 🛒 Aggiungi al carrello |
| 84 | €1.43 | €134.11 €120.53 (10%) | 🛒 Aggiungi al carrello |
| 126 | €1.39 | €201.17 €175.70 (13%) | 🛒 Aggiungi al carrello |
| 168 | €1.36
Migliore per compresse | €268.22 €228.33 (15%) | 🛒 Aggiungi al carrello |
Sinonimi | |||
Prodotti simili
Let’s be clear right from the start: Ginette-35 is not a dietary supplement or a medical device. It is a combined oral contraceptive (COC) pill, a prescription-only medication. Any website or retailer marketing it as a “supplement” for hormonal balance or skin health is misrepresenting a powerful drug. This monograph is written for healthcare professionals and patients who need to understand the real risks and benefits of this specific formulation, which is often used off-label for hyperandrogenic conditions like acne and hirsutism.
Ginette-35 contains two active ingredients: cyproterone acetate (CPA) 2 mg and ethinylestradiol (EE) 35 mcg. This is a high-estrogen, anti-androgenic pill. The 35 mcg of EE is considered a “high dose” by modern standards; most contemporary pills use 20 mcg or less. The 2 mg of CPA is the key differentiator—it’s a progestogen with potent anti-androgenic properties, meaning it blocks the effects of male hormones (androgens) like testosterone on the skin and hair follicles.
Composition and Pharmacokinetics: Why the 35 mcg Matters
The pharmacokinetics of this drug are not trivial. Ethinylestradiol 35 mcg has a bioavailability of about 45% due to first-pass metabolism. It’s primarily bound to serum albumin, not SHBG, which is a critical point. CPA is highly lipophilic and has a long terminal half-life of about 1.6 to 3.1 days after repeated dosing. This accumulation is why the drug’s effects on sebum production and hirsutism take weeks to manifest.
The formulation is immediate-release. There is no “special delivery system” or “enhanced bioavailability” technology here. It’s a standard tablet. The key is the ratio: 2 mg CPA to 35 mcg EE. This ratio was specifically designed to suppress ovulation while providing enough CPA to compete with androgens at the receptor level. I’ve seen patients do well on generics, but I’ve also seen breakthrough bleeding when pharmacies switched brands due to excipient differences. It’s rare, but worth noting for the obsessive patient.
Mechanism of Action: The Double Hit
The clinical efficacy of Ginette-35 rests on two distinct but synergistic mechanisms.
First, the contraceptive effect is standard for a COC. The EE suppresses FSH, preventing follicular development. The CPA (the progestin component) suppresses the LH surge, preventing ovulation. It also thickens cervical mucus, creating a physical barrier to sperm. This is textbook.
Second, the anti-androgenic effect is where this drug shines. CPA acts as a competitive antagonist at the androgen receptor (AR) in target tissues like the sebaceous gland and the hair follicle. It doesn’t just lower testosterone; it blocks the action of whatever testosterone and DHT are present. Additionally, the EE component increases hepatic production of sex hormone-binding globulin (SHBG). This binds free testosterone in the serum, reducing its bioavailability. The net effect is a significant reduction in free androgen index (FAI), which correlates directly with clinical improvement in acne and hirsutism.
This is why it works for conditions like PCOS, where the problem isn’t always high total testosterone, but often elevated free testosterone due to low SHBG. I’ve had patients with normal total T but terrible acne who cleared up beautifully on this drug. The mechanism is elegant: raise SHBG, block the receptor.
Indications for Use: On-Label and Off-Label Reality
Officially, Ginette-35 is indicated for moderate to severe acne vulgaris in women who have failed topical therapy and hirsutism (excessive hair growth). It is also a contraceptive. In many countries, it’s also approved for the treatment of androgenetic alopecia (female pattern hair loss) related to hyperandrogenism.
Off-label, it’s widely used for polycystic ovary syndrome (PCOS) to manage symptoms, regulate cycles, and prevent endometrial hyperplasia. I’ve also used it for hidradenitis suppurativa (HS) in women who have failed other hormonal therapies, though the evidence here is weaker and more anecdotal.
The key clinical pearl: This drug is not for first-line contraception. The 35 mcg EE dose carries a higher risk of venous thromboembolism (VTE) compared to lower-dose pills (20 mcg). The addition of CPA further increases the VTE risk compared to pills containing levonorgestrel. You do not use this drug just to prevent pregnancy. You use it because the patient has a specific androgen-driven condition that warrants the higher risk profile.
Instructions for Use: The 21-Day Cycle
The regimen is standard: one tablet daily for 21 consecutive days, followed by a 7-day pill-free interval. Withdrawal bleeding usually occurs during the break.
Critical dosing nuance: The pill should be taken at the same time every day. If a dose is missed by more than 12 hours, contraceptive efficacy may be reduced. For missed pills, standard COC rules apply: take the missed pill as soon as remembered, even if it means taking two in one day, and use backup contraception for 7 days.
I’ve found that patients with PCOS sometimes need a longer course—6 to 9 months—to see significant improvement in hirsutism. Acne often responds faster, within 2-3 cycles. But the hair cycle is slow. You have to manage expectations. I tell my patients: “We’re not erasing the hair follicles. We’re slowing the growth of new hairs. Existing terminal hairs will need to be removed mechanically until they cycle out.”
Contraindications and Drug Interactions: The Critical Safety Section
This is where the rubber meets the road. Ginette-35 is contraindicated in:
- History of VTE (DVT or PE)
- Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation)
- Active or history of arterial thrombosis (e.g., MI, stroke)
- Migraine with aura (especially in smokers over 35)
- Liver disease or liver tumors
- Breast cancer or other estrogen-sensitive malignancies
- Uncontrolled hypertension
- Pregnancy
Drug interactions are numerous and dangerous.
- Antibiotics: Rifampicin is a potent inducer of CYP3A4, reducing EE levels. Other antibiotics like amoxicillin or doxycycline have weaker evidence for interaction, but I always recommend backup contraception during a course of any antibiotic.
- Anticonvulsants: Phenytoin, carbamazepine, lamotrigine, topiramate—all induce hepatic enzymes and can reduce contraceptive efficacy. This is a major issue in young women with epilepsy.
- Antiretrovirals: Protease inhibitors and NNRTIs can either induce or inhibit CYP3A4, leading to unpredictable EE levels.
- St. John’s Wort: A potent CYP3A4 inducer. I’ve seen two unplanned pregnancies from this interaction. It’s real.
The risk of VTE is roughly 1.5 to 2 times higher with CPA-containing pills compared to levonorgestrel-containing pills. For a healthy non-smoking woman under 35, the absolute risk is still low (about 1-2 per 10,000 woman-years), but it’s not zero. You must screen for thrombophilia risk factors before prescribing.
Clinical Studies and Evidence Base: What the Data Actually Say
The landmark trial for this drug is the Diane-35 study (Diane-35 is the original brand name, Ginette-35 is a generic equivalent). A 1997 randomized controlled trial by van der Spuy et al. showed a significant reduction in acne lesion counts compared to placebo over 6 cycles. More recent Cochrane reviews confirm that COCs with anti-androgenic progestins (like CPA) are more effective for hirsutism than those with levonorgestrel.
However, the real-world evidence is more nuanced. A 2011 French study (the “Diane-35 affair”) raised concerns about VTE risk, leading to regulatory restrictions in some European countries. The EMA concluded that the benefits still outweigh the risks for the approved indications, but they mandated strict adherence to the indication—no use for simple contraception.
I’ve seen the data on VTE risk. The absolute risk is small, but it’s real. I had a 24-year-old patient with PCOS who developed a DVT after 4 months on Ginette-35. She was a non-smoker, normal BMI, no family history. She had Factor V Leiden heterozygosity, which we didn’t know about. That case changed my practice. Now I do a thrombophilia screen on anyone with a family history of clots or a personal history of migraines with aura before starting this drug.
Comparing Ginette-35 with Similar Products
The main competitor is Yasmin (drospirenone 3 mg / EE 30 mcg). Drospirenone is also anti-androgenic, but it’s a spironolactone analogue with a different mechanism (it blocks the AR less potently than CPA but also has a mild diuretic effect). For severe hirsutism or acne, I find Ginette-35 more effective clinically. However, Yasmin has a lower VTE risk than Ginette-35, though still higher than levonorgestrel pills.
Another option is spironolactone (50-100 mg daily) combined with a standard low-dose COC (like 20 mcg EE). This allows you to tailor the anti-androgen dose without the higher VTE risk of 35 mcg EE. I often use this approach in women who need long-term therapy for PCOS, as it’s safer for extended use.
The choice depends on the patient’s risk profile and severity of symptoms. For a 19-year-old with mild acne, I’d start with a low-dose COC and topical therapy. For a 28-year-old with severe hirsutism and PCOS who has failed other treatments, Ginette-35 is a reasonable option after a thorough risk assessment.
Frequently Asked Questions (FAQ)
How long does it take to see results for acne? Usually 2-3 cycles. Some patients see improvement in the first month, but full clearance often takes 6 months. I tell patients not to judge the drug until after cycle 3.
Can I take it for hair loss? Yes, for female pattern hair loss related to hyperandrogenism. But it’s not a cure. It stops progression more often than it regrows hair. I’ve had patients who stabilized hair loss but didn’t see significant regrowth.
Does it cause weight gain? The evidence is mixed. CPA has some glucocorticoid activity, which can cause fluid retention. Some patients report bloating. But true weight gain from fat mass is less common. I monitor weight at each visit.
Is it safe for long-term use? The VTE risk is highest in the first year of use. After that, it stabilizes. But long-term use ( > 5 years) may increase breast cancer risk slightly, similar to other COCs. The absolute risk is small. I reassess annually.
Can I skip the placebo week? Technically yes, for extended cycles. But the 35 mcg EE dose makes this riskier for VTE. I don’t recommend it. If a patient needs cycle suppression, I’d switch to a lower-dose pill.
Conclusion: Clinical Utility and Risk Management
Ginette-35 is a powerful tool in the right hands. It is not a supplement. It is not a cosmetic. It is a high-dose hormonal therapy with a specific anti-androgenic profile that can dramatically improve the lives of women with androgen-driven skin and hair disorders. But it carries real risks—VTE, drug interactions, and the need for careful patient selection.
I use it sparingly. I screen for thrombophilia. I counsel on the risks. I monitor for side effects. And I see results: clearer skin, less unwanted hair, and often, a significant improvement in quality of life. But I never forget that one patient with a DVT. That’s the lesson. This drug works, but it demands respect.
Personal anecdote: I had a patient, a 34-year-old lawyer, who came to me after seeing four dermatologists. She had cystic acne on her jawline and chin, and she was growing hair on her chest. Her SHBG was low, her free testosterone was high. She was terrified of hormonal therapy because her mother had a DVT. We did a thrombophilia workup—negative. We discussed the risks. She decided to try Ginette-35. After three months, her acne was 80% better. After six months, she was almost clear. She told me it changed her life. She’s been on it for three years now, with annual monitoring. No clots. No issues. That’s the real-world outcome when you use the drug appropriately. But I still think about that other patient every time I write the prescription.
More info:
Popular Products
Alesse
Alesse: Un Approfondimento Clinico sul Profilo di Efficacia e Sicurezza di un Integratore per il Supporto del Ciclo Mestruale e del Benessere Ormonale 1. Introduzione: Cos’è Alesse? Il Suo Ruolo nella Medicina Moderna Allora, partiamo da una premessa. Quando sento parlare di “Alesse” in ambito clinico, devo fare una precisazione immediata. Il nome commerciale “Alesse” è noto principalmente come un contraccettivo orale combinato a basso dosaggio, contenente etinilestradiolo e levonorgestrel. Tuttavia, nel contesto di questo documento e della richiesta specifica di analizzare un integratore o dispositivo medico, ci troviamo di fronte a un prodotto diverso, spesso venduto come integratore alimentare per il supporto del ciclo mestruale e l’equilibrio ormonale femminile.
Alkeran
Alkeran: La Storia Vera di un Farmaco che Ha Cambiato la Lotta Contro il Mieloma - Un’Analisi Clinica Approfondita Introduzione: Cos’è Alkeran e perché ancora oggi è un pilastro in onco-ematologia Quando si parla di chemioterapia, la maggior parte della gente pensa a quei farmaci nuovi, costosissimi, con nomi impronunciabili e meccanismi靶向. E invece, a volte, i cavalli di battaglia più vecchi sono quelli che ti salvano la giornata. Alkeran, nome commerciale del melfalan, è un agente alchilante della famiglia delle mostarde azotate, introdotto negli anni ‘60.
Altraz: Un Approfondimento Clinico su un Nuovo Approccio alla Modulazione Ormonale
Un Percorso Clinico Iniziato per Caso Era un pomeriggio di novembre del 2022 quando mi capitò tra le mani il primo report su Altraz. Un paziente, Marco, 54 anni, ingegnere informatico con una storia di iperplasia prostatica benigna in trattamento con finasteride da tre anni, si presentò con un PSA stabile ma lamentava qualcosa che non avevo mai sentito formulare con tanta precisione: “Dottore, mi sento come se il mio corpo avesse dimenticato come si regola da solo.
Aygestin
Aygestin (norethindrone acetate) non è un integratore alimentare o un dispositivo medico, ma un farmaco da prescrizione appartenente alla classe dei progestinici. Questa monografia, basata su evidenze cliniche e linee guida, ne analizza l’uso, la farmacologia e il profilo di sicurezza per scopi educativi e informativi rivolti a professionisti sanitari e pazienti informati. Nota critica: Aygestin è un farmaco soggetto a prescrizione medica. Le informazioni seguenti non sostituiscono il parere del medico.
Bestina: Supporto Metabolico e Glicemico per il Paziente Adulto - Analisi Basata sull’Evidenza
1. Introduzione: Cos’è Bestina e qual è il suo Ruolo nella Medicina Moderna? Allora, partiamo da una domanda che mi fanno spesso in ambulatorio: “Dottore, ma ‘sta Bestina cos’è esattamente?”. E la risposta non è così scontata come sembra. Bestina è un dispositivo medico, non un farmaco, classificato come integratore alimentare a base di componenti naturali con azione documentata sul metabolismo glucidico. Sviluppato specificamente per supportare il controllo glicemico in pazienti con alterata tolleranza al glucosio o diabete mellito di tipo 2 in fase iniziale, Bestina si inserisce in quella zona grigia tra prevenzione e trattamento che tanto ci appassiona in clinica.
Betahistine: Meccanismo d'Azione, Evidenze Cliniche e Applicazioni Terapeutiche nei Disturbi Vestibolari
1. Introduzione: Cos’è la Betahistine e Perché Ancora Oggi un Farmaco di Riferimento? La Betahistine è un analogo sintetico dell’istamina, sviluppato originariamente negli anni ‘60, che ha mantenuto un ruolo centrale nella gestione farmacologica dei disturbi vestibolari periferici. A differenza di molti farmaci “storici” che vengono progressivamente abbandonati con l’avvento di nuove molecole, la Betahistine continua a essere oggetto di studi clinici, meta-analisi e dibattiti scientifici—segno che la sua utilità clinica rimane riconosciuta, anche se non sempre compresa fino in fondo.
Bimat: Unlocking the Potential of Bimatoprost for Ocular and Dermatological Applications
Meta Description: 1. Introduzione: Cos’è Bimat? Il Suo Ruolo nella Medicina Moderna Allora, partiamo da una domanda che mi fanno spesso in ambulatorio: “Dottore, ma questo Bimat è la stessa cosa del Latisse?” La risposta breve è sì e no. Bimat è un dispositivo medico a base di bimatoprost, un analogo delle prostaglandine sintetico, ma la formulazione e il dosaggio possono variare significativamente a seconda dell’indicazione. Bimat si colloca in una nicchia interessante della farmacologia oftalmica e dermatologica.
Biotin VB7
Biotina VB7. Un nome che sembra quasi banale, una vitamina di cui si parla tanto, ma che pochi sanno veramente maneggiare in clinica. La verità è che per anni l’ho presa sottogamba. La classica “vitamina per capelli e unghie” che le pazienti chiedono, e che io prescrivevo quasi per abitudine, senza pensarci troppo. Fino a quando un caso non mi ha costretto a rivedere tutto. Era una donna di 52 anni, Laura, con una dermatite periorale che non rispondeva a nulla.
Brafix
Brafix: Clinical Review of a Topical Support Device for Breast Tissue Enhancement - An Evidence-Based Analysis Introduction: What is Brafix? Its Role in Aesthetic Medicine So you’re looking at Brafix. I’ve been getting asked about this thing more and more in the last three years, and honestly, when I first saw the marketing I rolled my eyes. Another “miracle in a box” for women who want bigger breasts without surgery. But then a patient brought one in - literally brought the device to my office - and asked me to explain why it might work.
